Komori
Takara Bio (4974) · RiskRestated

Risks Relating to Patent Registration, Validity, Obsolescence and Dependence on Third-Party Patents

First written in FY2016. 20 of 24 entries say "Restated". Latest entry: FY2025-H1.

24entries
9years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2018-Q1RestatedFY2019-Q1 – FY2023-Q32016: 320162017: 320172018: 320182019: 220192020: 320202021: 220212022: 320222023: 220232024: 32024
Same theme, other companies

The whole theme swung hardest in 2020: 4 of 43 companies on the "Worse" side.

64 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 108 companies compared. The sentences above are computed from all 108.
Full recordFilings, disclosures and news, newest first
  1. FY2025-H1RestatedAnnual report

    「During the current interim consolidated accounting period, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the previous fiscal year.」

    特許の登録・有効性・陳腐化および他者特許への依存リスクについて、新規発生または重要な変更はないとしている。
  2. FY2024RestatedAnnual report

    「しかしながら、出願した特許がすべて登録されるとは限らず、また、登録特許が無効となる、消滅する等した場合には、当社グループの事業戦略や経営成績に影響を及ぼす可能性があります。」

    自社特許の登録・有効性・消滅および他者特許の取得・ライセンスに関するリスクを継続して記載している。
  3. FY2024-Q3RestatedAnnual report

    「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    特許の登録・有効性・陳腐化および他者特許への依存リスクについて、新規発生または重要な変更はないとしている。
  4. FY2023MaterialisedAnnual report

    「(注)2023年3月に権利満了となりました。」

    レトロネクチン拡大培養法に関する複数国の特許について、2023年3月の権利満了を開示した。
  5. FY2023-Q3RestatedAnnual report

    「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    特許の登録・有効性・陳腐化および他者特許への依存リスクについて、新規発生または重要な変更はないとしている。
  6. FY2023-Q2RestatedAnnual report

    「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    特許の登録・有効性・陳腐化および他者特許への依存リスクについて、新規発生または重要な変更はないとしている。
  7. FY2023-Q1RestatedAnnual report

    「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    特許の登録・有効性・陳腐化および他者特許への依存リスクについて、新規発生または重要な変更はないとしている。
  8. FY2022-Q3RestatedAnnual report

    「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    特許の登録・有効性・陳腐化および他者特許への依存リスクについて、新規発生または重要な変更はないとしている。
  9. FY2022-Q2RestatedAnnual report

    「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    特許の登録・有効性・陳腐化および他者特許への依存リスクについて、新規発生または重要な変更はないとしている。
  10. FY2022-Q1RestatedAnnual report

    「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    特許の登録・有効性・陳腐化および他者特許への依存リスクについて、新規発生または重要な変更はないとしている。
  11. FY2021-Q2RestatedAnnual report

    「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    特許の登録・有効性・陳腐化および他者特許への依存リスクについて、新規発生または重要な変更はないとしている。
  12. FY2021-Q1RestatedAnnual report

    「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    特許の登録・有効性・陳腐化および他者特許への依存リスクについて、新規発生または重要な変更はないとしている。
  13. FY2020-Q3RestatedAnnual report

    「No new business or other risks arose during the nine months ended 31 December. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」

    特許の登録・有効性・陳腐化および他者特許への依存リスクについて、重要な変更はないとしている。
  14. FY2020-Q2RestatedAnnual report

    「No new business or other risks arose during the six months ended 30 September. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」

    特許の登録・有効性・陳腐化および他者特許への依存リスクについて、重要な変更はないとしている。
  15. FY2019-Q3RestatedAnnual report

    「No new business or other risks arose during the nine months ended [the current third quarter]. There have also been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    特許の登録・有効性・陳腐化および他者特許への依存リスクについて、重要な変更はないとしている。
  16. FY2019-Q2RestatedAnnual report

    「During the cumulative second quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」

    特許の登録・有効性・陳腐化および他者特許への依存リスクについて、重要な変更はないとしている。
  17. FY2019-Q1RestatedAnnual report

    「During the first quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」

    特許の登録・有効性・陳腐化および他者特許への依存リスクについて、重要な変更はないとしている。
  18. FY2018-Q3MaterialisedAnnual report

    「当契約につきましては、平成29年11月21日をもって満了となりました。」

    Life Technologies CorporationとのPCR法・リアルタイムPCR法等に関するライセンス契約が契約期間満了により終了した。
  19. FY2018-Q2MaterialisedAnnual report

    「なお、当社は本契約終了とともに、本契約に基づいて取得した特許をインディアナ大学に譲渡することとなっております。」

    レトロウイルスベクターによる高効率遺伝子導入法に関するインディアナ大学との独占的ライセンス契約が契約期間満了により終了し、取得特許を同大学へ譲渡することとなった。
  20. FY2018-Q1RestatedAnnual report

    「During the first quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」

    特許の登録・有効性・陳腐化および他者特許への依存リスクについて、重要な変更はないとしている。
  21. FY2017-Q3RestatedAnnual report

    「No new business or other risks arose during the nine months ended [the current third quarter]. There have also been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    特許の登録・有効性・陳腐化および他者特許への依存リスクについて、重要な変更はないとしている。
  22. FY2017-Q2RestatedAnnual report

    「During the cumulative second quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」

    特許の登録・有効性・陳腐化および他者特許への依存リスクについて、重要な変更はないとしている。
  23. FY2017-Q1RestatedAnnual report

    「During the first quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」

    特許の登録・有効性・陳腐化および他者特許への依存リスクについて、重要な変更はないとしている。
  24. FY2016First statedAnnual report

    「However, not all filed patent applications will necessarily be granted, and if granted patents become invalid for any reason or lapse because their terms expire, this may affect the Group’s business strategy and financial results.」

    Discloses a policy of protecting the Group’s own patents while acquiring or licensing promising third-party patents, and the potential impact if licenses cannot be obtained.
Moved together

"Foreign-Exchange Risk from Foreign-Currency Transactions and Overseas Subsidiaries" moved the same way as this thread, in the same document, in 3 of its 24 moves.

3★1
  1. ★This thread
  2. 1Foreign-Exchange Risk from Foreign-Currency Transactions and Overseas Subsidiaries3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Takara Bio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.